Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

@article{Jeppesen1996DosedependentIO,
  title={Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine},
  author={U. Jeppesen and L. F. Gram and K. Vistisen and S. Loft and H. Poulsen and K. Br{\o}sen},
  journal={European Journal of Clinical Pharmacology},
  year={1996},
  volume={51},
  pages={73-78}
}
  • U. Jeppesen, L. F. Gram, +3 authors K. Brøsen
  • Published 1996
  • Medicine
  • European Journal of Clinical Pharmacology
  • Objectives: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine. [...] Key Method The volunteers received in randomised order, at weekly intervals, increasing single oral doses of one of the four SSRIs, followed 3 h later by sparteine (CYP2D6), mephenytoin (CYP2C19) and caffeine (CYP1A2) tests. Fluoxetine…Expand Abstract
    297 Citations
    The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
    • 38
    • Highly Influenced
    • PDF
    Inhibition and possible induction of rat CYP2D after short‐ and long‐term treatment with antidepressants
    • 25
    Pharmacokinetics of selective serotonin reuptake inhibitors.
    • 671
    Dose‐Dependent Alternations in the Pharmacokinetics of Olanzapine During Coadministration of Fluvoxamine in Patients With Schizophrenia
    • 23

    References

    SHOWING 1-10 OF 47 REFERENCES
    Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
    • 185
    Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
    • 145
    Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *
    • 97
    A fluvoxamine-caffeine interaction study.
    • 98
    Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms
    • 204
    Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms
    • 86